GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Inventories, Raw Materials & Components

VRAX (Virax Biolabs Group) Inventories, Raw Materials & Components : $0.05 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Inventories, Raw Materials & Components?

Virax Biolabs Group's inventories, raw materials & components for the quarter that ended in Sep. 2024 was $0.05 Mil.

Virax Biolabs Group's quarterly raw materials stayed the same from Sep. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil) but then increased from Mar. 2024 ($0.00 Mil) to Sep. 2024 ($0.05 Mil).


Virax Biolabs Group Inventories, Raw Materials & Components Historical Data

The historical data trend for Virax Biolabs Group's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Inventories, Raw Materials & Components Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Inventories, Raw Materials & Components
- - - - -

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.05

Virax Biolabs Group Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Virax Biolabs Group Business Description

Industry
Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.